A Form 4 filed with the SEC on August 26, 2026, reports that Marc N. Casper, Chairman and Chief Executive Officer of Thermo Fisher Scientific Inc. (NYSE:TMO), exercised stock options and sold common stock on August 24, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Casper exercised a stock option for 275 shares of common stock at an exercise price of $309.63 per share on August 24, 2026.
  • Shares sold: A total of 275 shares were sold across four separate tranches at weighted average prices ranging from $625.41 to $628.74 per share.
  • Post-transaction ownership: Following the transactions, Casper directly beneficially owned 123,925.358 shares of common stock.
  • Indirect holdings: Casper also holds 5,000 shares indirectly through the MNC 2020 Irrevocable Trust and 11,300 shares indirectly through the Alison Casper 2020 Irrevocable Trust.
  • 10b5-1 plan: According to the filing, the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Casper on April 27, 2026.
  • Option vesting: The filing states the exercised option "vested in four equal installments on February 25, 2021, 2022, 2023, and 2024."

Details of Casper's August 24, 2026 Transactions in Thermo Fisher Scientific Stock

According to the Form 4 filed on August 26, 2026, Marc N. Casper acquired 275 shares of Thermo Fisher Scientific common stock via a stock option exercise coded "M," at a conversion price of $309.63 per share. Immediately following that acquisition, the filing reports that Casper sold all 275 shares across four separate sale transactions, all coded "S," on the same date of August 24, 2026.

The four sale tranches are reported as follows: 101 shares at a weighted average price of $625.41 (with individual transaction prices ranging from $625.00 to $625.98); 33 shares at a weighted average price of $626.59 (ranging from $626.25 to $627.21); 79 shares at a weighted average price of $628.01 (ranging from $627.43 to $628.34); and 62 shares at a weighted average price of $628.74 (ranging from $628.48 to $628.89). The filing notes that Casper undertakes to provide full information on shares sold at each separate price within these ranges upon request.

The filing indicates that all sale transactions were made under a Rule 10b5-1 trading plan Casper adopted on April 27, 2026. Regarding indirect holdings, the filing states that Casper "disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein." The Form 4 was signed by Melodie T. Morin as Attorney-in-Fact for Marc N. Casper on August 26, 2026.

What Was Disclosed

The filing discloses a same-day option exercise and share sale by Thermo Fisher Scientific's Chairman and CEO on August 24, 2026, carried out under a pre-established Rule 10b5-1 plan. After the transactions, Casper directly held 123,925.358 shares.